Samsung Biologics

207940.KO

683.20 USD

0.73

+0.11%

Overview

Last close

683.20 usd

Market cap

31.63B usd

52 week high

761.21 usd

52 week low

522.84 usd

Target price

685.6 usd

Valuation

P/E

N/A

Forward P/E

42.0168

Price/Sales

11.233

Price/Book Value

7.4899

Enterprise Value

59.43B usd

EV/Revenue

17.2261

EV/EBITDA

38.2422

Key financials

Revenue TTM

3.45B usd

Gross Profit TTM

1.81B usd

EBITDA TTM

1.56B usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

13.13B usd

Net debt

465.98M usd

About

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.